TICKERNERD
Menu
UNCYUNCYHealthcare · Biotechnology

UNCY Stock Forecast: Unicycive Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.29
−0.38% on the day

The 9 Wall Street analysts covering Unicycive Therapeutics, Inc. hold a median 12-month price target of $25 — +372.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$144.9M
Ticker Nerd rank
35 / 100
Median analyst target
$25
Analysts covering
9
Revenue$0.0
Operating income−$10.1M
Net income−$1.7M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
+5.8%
YTD
−8.3%
1Y
+29.3%
From 52W high
−38.2%
From 52W low
+41.4%
$3.74
$8.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

UNCY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Unicycive Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
72
Accruals
65
Volatility
60
Revisions
47
Quality
47
Momentum
43
Growth
37
Value
30
Issuance
17

Size (72): Smaller than most of the companies we track.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

UNCY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UNCY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00Oct 25Jan 26Apr 26Jul 26UNCYHigh $50Median $25Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $15Median $25High $50

The green dot is the last close — the median target sits +372.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
20 Aug 2026BenchmarkMaintainsSpeculative Buy$13 → $15
13 Aug 2026B. Riley SecuritiesReiteratesBuy$22 → $20
13 Aug 2026GuggenheimMaintainsBuy$37 → $25
1 July 2026BenchmarkMaintainsSpeculative Buy$18 → $13
1 July 2026BenchmarkMaintainsSpeculative Buy—
1 July 2026Noble Capital MarketsMaintainsOutperform—
1 July 2026Noble Capital MarketsMaintainsOutperform$60 → $50
30 June 2026B. Riley SecuritiesMaintainsBuy—
30 June 2026B. Riley SecuritiesMaintainsBuy$22
30 June 2026HC Wainwright & Co.MaintainsBuy—
30 June 2026HC Wainwright & Co.MaintainsBuy$22 → $15
2 June 2026BenchmarkMaintainsSpeculative Buy—
13 May 2026GuggenheimMaintainsBuy—
6 Apr 2026BenchmarkMaintainsSpeculative Buy—
2 Apr 2026GuggenheimMaintainsBuy—
29 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Sept 2025BenchmarkMaintainsSpeculative Buy—
27 May 2025HC Wainwright & Co.AssumesBuy$9.00
21 Apr 2025GuggenheimInitiatesBuy—
11 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UNCY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

UNCY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Unicycive Therapeutics, Inc. returned +29.3% against +17.5% for the S&P 500, dividends included.

UNCY vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26UNCYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

UNCY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Unicycive Therapeutics, Inc. (UNCY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
2.8×

Cheaper than 35% of US stocks

EV / EBITDA
−2.6×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−101.1%

Higher than 13% of US stocks

Return on assets
−40.6%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Unicycive Therapeutics, Inc. (UNCY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Unicycive Therapeutics, Inc. has a market value of $144.9M and an enterprise value of $86.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$35.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$27.8M.

  • Shares outstanding: 27.9M.

  • Trailing P/E: −3.2×; forward P/E: 3.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Unicycive Therapeutics, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

UNCY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
UNCYUnicycive Therapeutics, Inc.$144.9M
35
LENZLENZ Therapeutics, Inc.$141.4M
24
NRXPNRX Pharmaceuticals, Inc.$142.6M
20
TNYATenaya Therapeutics, Inc.$138.6M
37
CRBUCaribou Biosciences, Inc.$136.2M
57
MENSJyong Biotech Ltd.$147.7M
3
EQEquillium, Inc.$133.4M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Unicycive Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UNCY news & analysis

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 11 Sept 2026negative

A law firm announced that investors who suffered losses on Unicycive Therapeutics, Inc. stock have the opportunity to lead a securities fraud class action lawsuit against the company. The announcement seeks affected shareholders to come forward.

Why it matters — UNCY watchers would care because the company is facing a securities fraud class action lawsuit that could carry legal and reputational consequences.

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors with Significant Losses to Contact the Firm Before November 2, 2026

Newsfile Corp · 11 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Unicycive Therapeutics on behalf of investors who acquired UNCY securities between December 29, 2025 and June 29, 2026. The firm is encouraging affected investors with significant losses to contact them before November 2, 2026.

Why it matters — A class action lawsuit against the company relating to its securities during a defined class period could indicate legal and financial exposure for UNCY shareholders.

UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

Business Wire · 11 Sept 2026negative

Kirby McInerney LLP has issued an investor reminder for Unicycive Therapeutics, Inc. regarding an ongoing securities fraud class action lawsuit, noting that affected investors have until November 2, 2026 to apply to be appointed as lead plaintiff.

Why it matters — A UNCY watcher would care because it highlights an active securities fraud class action against the company that could affect shareholder value and legal exposure.

FAQ

Frequently asked questions about UNCY stock

What is the UNCY stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Unicycive Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $15 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is UNCY stock a buy right now?

Of the 9 analysts covering Unicycive Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Unicycive Therapeutics, Inc. 35 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank UNCY?

As at 12 Sept 2026, Unicycive Therapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).

Will UNCY stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +372.6% from the last close, and Ticker Nerd's factor model ranks Unicycive Therapeutics, Inc. 35 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the UNCY stock forecast for 2030?

No analyst covering Unicycive Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UNCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $50 over the next 12 months.

How has UNCY stock performed over the past year?

Unicycive Therapeutics, Inc. returned +29.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Unicycive Therapeutics, Inc. do?

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases.

What is the latest news on UNCY?

The most recent item we track (PRNewsWire, 11 Sept 2026): "Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit". A law firm announced that investors who suffered losses on Unicycive Therapeutics, Inc. stock have the opportunity to lead a securities fraud class action lawsuit against the company. The announcement seeks affected shareholders to come forward.

Company

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases. Its current pipeline centers on treatments for chronic kidney disease-related hyperphosphatemia and acute kidney injury, including oxylanthanum carbonate, a phosphate-binding agent designed for patients on dialysis, and UNI-494, a drug candidate being studied for kidney injury-related conditions. The company operates in the nephrology-focused biopharmaceutical market, where it works to address unmet medical needs through drug development and commercialization activities. Unicycive Therapeutics also evaluates additional renal and metabolic opportunities, reflecting its focus on specialized therapies for complex kidney conditions.

CEO Dr. Shalabh K. Gupta M.D., MPA · 21 employees · United States · https://unicycive.com